The global digital biomanufacturing market size was valued at USD 23.39 billion in 2025 and is projected to grow from USD 26.06 billion in 2026 to USD 62.58 billion by 2034, registering a CAGR of 11.58% during the forecast period (2026–2034). North America dominated the digital biomanufacturing market with a market share of 40.23% in 2025.
Digital biomanufacturing refers to the integration of advanced digital technologies, automation, AI, data analytics, and connected software platforms into biopharmaceutical manufacturing processes. These solutions enable monitoring, predictive analytics, process optimization, and automated control across biologics production, improving product quality, operational efficiency, and regulatory compliance.
The digital biomanufacturing market demand is increasing due to growing biologics production, rising adoption of smart manufacturing technologies, and the need for efficient, data-driven manufacturing processes. Investments in Industry 4.0, expanding biopharmaceutical research, and continuous advancements in digital platforms, cloud computing, and process automation are further supporting digital biomanufacturing market growth.
Download a Free Sample to Explore Detailed Market Insights
The digital biomanufacturing market is exposed to supply chain disruptions because it depends on globally sourced automation hardware, industrial sensors, semiconductor chips, laboratory instrumentation, and specialized software. Disruptions in the availability of these critical technologies increase implementation costs, extend project timelines, delay equipment deployment, and slow biologics production worldwide. The market is expected to experience a capacity-constrained recovery, with growth steadily improving as component supplies normalize, infrastructure investments increase, and digital adoption accelerates across global biomanufacturing operations.
Biopharmaceutical companies are increasingly adopting AI-enabled digital twins to simulate, monitor, and optimize manufacturing processes throughout the biologics production lifecycle. Rather than relying solely on historical process data, these virtual models provide real-time insights that improve process efficiency, reduce batch failures, and accelerate scale-up. For example, Siemens and Sartorius have collaborated to integrate digital twin capabilities into bioprocessing environments, enabling predictive process optimization and decision-making across biomanufacturing operations.
The market is witnessing a transition from manually supervised production to autonomous, closed-loop manufacturing systems that continuously analyze process data and automatically adjust operating parameters. This trend enhances manufacturing efficiency, minimizes human intervention, and strengthens regulatory compliance through process control. For example, Thermo Fisher Scientific has introduced digitally connected bioprocessing solutions that combine automation, analytics, and software to enable intelligent and highly automated biologics manufacturing.
The digital biomanufacturing market forecasts continued investment activity driven by the rapid adoption of AI-enabled bioprocessing, cloud-based manufacturing platforms, and smart biologics production. Investors are focusing on companies developing digital infrastructure, automation software, and connected biomanufacturing platforms that improve process efficiency and strengthen regulatory compliance across biologics manufacturing.
In December 2025, Culture Biosciences announced the successful close of its Series C financing round to accelerate the commercialization of its Stratyx 250 cloud-connected bioreactor platform and expand its AI-enabled Console software ecosystem for digital biomanufacturing. The investment will support product development, scale manufacturing capacity, and strengthen customer deployment across biopharmaceutical organizations.
Regulatory Shift toward Real-time Process Monitoring and Rising Adoption of Continuous Bioprocessing Drives Market
Regulatory agencies are increasingly encouraging manufacturers to adopt digital process monitoring and data-driven quality management throughout biologics production. This is driving demand for digital biomanufacturing platforms that provide continuous process verification, electronic batch records, and automated documentation to improve compliance and reduce product release timelines. As manufacturers modernize quality systems, investments in integrated digital manufacturing solutions continue to increase.
The transition from traditional batch manufacturing to continuous bioprocessing is increasing the need for digital platforms capable of monitoring, analyzing, and controlling production in real time. Continuous operations generate large volumes of process data that require advanced automation, AI, and analytics to maintain consistent product quality and maximize manufacturing efficiency. This shift is accelerating demand for integrated digital biomanufacturing solutions across commercial biologics facilities.
Complex Integration with Legacy Manufacturing Infrastructure and High Validation Burden for AI-based Process Changes Restrain Market Expansion
Many biopharmaceutical manufacturing facilities continue to operate with legacy automation systems, standalone laboratory instruments, and fragmented data architectures that are not designed for modern digital platforms. Integrating advanced digital biomanufacturing solutions often requires significant infrastructure upgrades, system validation, and process redesign, increasing implementation costs and deployment timelines.
AI-enabled digital biomanufacturing platforms continuously generate recommendations for process optimization based on real-time manufacturing data and predictive analytics. Any modification affecting critical process parameters requires extensive scientific validation, regulatory documentation, and comparability assessments before implementation in GMP production. This increases deployment time and reduces manufacturers' willingness to apply autonomous optimization in commercial biologics facilities.
Expansion of Cell & Gene Therapy Manufacturing and Adoption of Digital Process Analytical Technology Offers Growth Opportunities to Market Players
The rapid commercialization of cell and gene therapies is creating specialized opportunities for digital biomanufacturing solutions capable of managing patient-specific production workflows, chain of identity, chain of custody, and real-time batch release. Unlike conventional biologics manufacturing, these therapies require digital coordination across manufacturing, quality control, logistics, and clinical delivery.
The growing industry shift toward real-time release testing is creating significant opportunities for digital biomanufacturing solution providers. Manufacturers are integrating process analytical technology, advanced sensors, and predictive analytics to monitor critical quality attributes throughout production, reducing dependence on end-product testing and shortening product release cycles. For example, continuous bioprocessing facilities are deploying Raman spectroscopy integrated with AI-based analytics to enable real-time monitoring of cell culture conditions and support faster batch release decisions.
System Interoperability and Digital Model Scalability Challenges Market Growth
A key challenge for the digital biomanufacturing market is achieving seamless interoperability between equipment supplied by different manufacturers throughout the bioprocessing workflow. Bioreactors, chromatography systems, filtration units, analytical instruments, and manufacturing software often use proprietary communication protocols and data formats, making end-to-end data integration difficult. As manufacturers pursue fully connected production environments, inconsistent data exchange limits process visibility, reduces automation efficiency, and increases the complexity of building unified digital biomanufacturing ecosystems.
Maintaining the accuracy of digital models when transitioning from laboratory-scale process development to commercial-scale biologics production remains a significant challenge. Process behavior often changes with scale due to variations in mixing dynamics, oxygen transfer, nutrient gradients, and equipment configuration, reducing the predictive reliability of AI models and digital twins.
By type, the manufacturing technologies segment accounted for a share of 40.76% in 2025, owing to widespread deployment of digitally enabled bioreactors and filtration systems across commercial biologics facilities. These assets continuously generate operational data, making manufacturing technologies the foundation for implementing automation and digital biomanufacturing in large-scale production.
The data analysis software segment is expected to grow at a CAGR of 11.95% during the forecast period, fueled by increasing adoption of predictive modeling, multivariate process analytics, and AI-driven decision support. Software platforms are becoming essential for extracting actionable insights from high-frequency bioprocess data while supporting real-time process optimization and faster manufacturing decisions.
By application, the biomanufacturing process automation & control segment accounted for a share of 43.20% in 2025. This is due to increasing deployment of automated control systems that continuously regulate critical process parameters throughout biologics manufacturing.
The bioprocess optimization segment is expected to grow at a CAGR of 12.03% during the forecast period, driven by increasing use of digital twins, advanced modeling, and AI algorithms to optimize upstream and downstream operations.
By end user, biopharmaceutical companies accounted for a share of 61.08% in 2025 due to extensive investments in commercial biologics manufacturing and enterprise-wide digital transformation initiatives. Their large production volumes, stringent quality requirements, and expanding biologics pipelines create sustained demand for integrated digital biomanufacturing platforms.
The CROs segment is expected to grow at a CAGR of 12.37% during the forecast period, driven by increasing outsourcing of process development, analytical characterization, and early-stage manufacturing activities. CROs are investing in digital biomanufacturing platforms to deliver faster project execution, standardized data management, and scalable development services for multiple clients.
North America: Market Dominance Led by Early Adoption of Pharma 4.0 Technologies and Increasing Deployment of Digital Twins
The North America digital biomanufacturing market accounted for the largest regional share of 40.23% in 2025, driven by the presence of leading biopharmaceutical manufacturers, early adoption of Pharma 4.0 technologies, and extensive investments in biologics, cell, and gene therapy production. The region also benefits from a mature life sciences innovation ecosystem, advanced automation capabilities, and strong collaboration between technology providers and biopharmaceutical companies. According to the International Society for Pharmaceutical Engineering, North America continues to lead global investments in digital pharmaceutical manufacturing and advanced bioprocessing infrastructure.
The US digital biomanufacturing market was valued at USD 8.22 billion in 2025, driven by increasing deployment of digital twins and cloud-based manufacturing execution systems across commercial biologics facilities. Biopharmaceutical companies are investing in connected manufacturing technologies to improve production efficiency, accelerate product commercialization, and strengthen regulatory compliance. The country's strong concentration of biotechnology firms, CDMOs, research institutions, and advanced biologics manufacturing facilities continues to support widespread adoption of digital biomanufacturing solutions.
The Canada digital biomanufacturing market size was valued at USD 1.19 million in 2025, supported by growing investments in domestic biomanufacturing capacity and increasing adoption of digital technologies for biologics and vaccine production. Government initiatives promoting biomanufacturing resilience, expansion of life sciences research infrastructure, and collaboration between academia and industry are encouraging the implementation of automated and data-driven manufacturing platforms.
Asia Pacific: Fastest Growth Driven by Establishment of Regional Biologics Manufacturing Hubs and Expanding Vaccine Manufacturing Exports
The Asia Pacific digital biomanufacturing market is expected to grow at a CAGR of 12.87% during the forecast period, showcasing the fastest regional growth. Growth is supported by the establishment of regional biologics manufacturing hubs, increasing government incentives for domestic biomanufacturing, and rising investments in contract manufacturing capabilities across emerging economies. The region is also witnessing growing adoption of smart bioprocessing technologies to improve manufacturing competitiveness. According to the Asian Development Bank, governments across Asia continue to prioritize life sciences manufacturing as a strategic industry for economic growth and healthcare resilience.
The China digital biomanufacturing market was valued at USD 1.36 billion in 2025, supported by growth of domestic biosimilar and monoclonal antibody manufacturing, implementation of intelligent manufacturing initiatives under the Made in China 2025 strategy, and increasing localization of bioprocess equipment production. The country's strong emphasis on reducing reliance on imported biopharmaceutical technologies is accelerating investments in AI-enabled production platforms, digital process control, and smart factory infrastructure.
The India digital biomanufacturing market was valued at USD 694.77 million in 2025, fueled by expanding vaccine and biosimilar manufacturing exports, growing adoption of digital manufacturing by domestic CDMOs, and increasing government support through initiatives such as the National Biopharma Mission. The country's cost-competitive manufacturing ecosystem and expanding biologics development pipeline are encouraging investments in cloud-based manufacturing execution systems.
The Japan digital biomanufacturing market was valued at USD 801.62 million in 2025, supported by Japan’s leadership in precision automation, increasing commercialization of regenerative medicine products, and widespread deployment of robotics within pharmaceutical manufacturing facilities. Strong collaboration between pharmaceutical companies, automation technology providers, and research institutes is accelerating the adoption of intelligent bioprocess control systems.
The digital biomanufacturing market competitive landscape is moderately consolidated, with competition led by established life sciences technology providers, industrial automation companies, and specialized bioprocess software developers. Leading players compete through AI-enabled process optimization, digital twin capabilities, cloud-based manufacturing platforms, advanced analytics, and integrated automation solutions. Companies are also expanding strategic collaborations with biopharmaceutical manufacturers and CDMOs to strengthen digital manufacturing capabilities. The digital biomanufacturing market ecosystem is shaped by increasing biologics production, Pharma 4.0 adoption, evolving regulatory expectations, and growing demand for connected manufacturing platforms that improve productivity, process consistency, and product quality.
April 2026: Thermo Fisher Scientific opened its flagship Bioprocess Design Center in the US to support biopharmaceutical manufacturers with process development, technology demonstrations, and scalable biologics manufacturing solutions.
September 2025: Siemens AG and TRUMPF announced a strategic partnership to accelerate digital manufacturing and AI readiness by combining Siemens' Xcelerator portfolio with TRUMPF's manufacturing software and machine technologies.
Customize This Report to Match Your Strategic Objectives
Author's Details
Research Analyst
Pavan Warade is a Research Analyst with over 4 years of expertise in Technology and Aerospace & Defense markets. He delivers detailed market assessments, technology adoption studies, and strategic forecasts. Pavan’s work enables stakeholders to capitalize on innovation and stay competitive in high-tech and defense-related industries.
We are featured on:
sales@straitsresearch.com